Results 51 to 60 of about 69,008 (285)

NIR Ratiometric Fluorescent Antibody‐Drug Conjugate for Metastatic Ovarian Cancer Theranostics and Treatment Response Monitoring

Advanced Science, EarlyView.
In vivo optical imaging enhances antibody‐drug conjugate (ADC) optimization by enabling real‐time monitoring of stimulus‐responsive drug behavior. We report n501‐CYMMAF, a ratiometric theranostic with strong target affinity and low‐dose efficacy for ovarian metastasis.
Cheng Li, Zezhong Yu, Tao Pu, Yanling Wu, Gang Wang, Youhua Xie, Tianlei Ying, Zhenlin Yang, Yibing Shi   +8 more
wiley   +1 more source

MARPLE: A Proximity‐Triggered CRISPR‐Cas13 Platform for Ultrasensitive Antibody Detection

Advanced Science, EarlyView.
MARPLE is a modular CRISPR‐Cas13 immunoassay that uses antibody‐induced proximity to trigger a toehold‐exchange reaction, releasing an RNA activator for Cas13. This one‐pot, isothermal architecture enables ultrasensitive (femtomolar) and highly specific detection of diverse antibodies, including therapeutic, pathogen‐specific, and cancer‐associated ...
Elena Spezzani, Luca Capelli, Denise Di Lena, Alejandro Chamorro‐Garcia, Rudy Ippodrino, Alessandro Porchetta, Alessandro Bertucci   +6 more
wiley   +1 more source

Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study

Oncology and Therapy
Introduction This study evaluated the pharmacokinetic (PK) equivalence between BP02 (a proposed trastuzumab biosimilar) and the reference trastuzumab approved in the EU (EU-trastuzumab) and the US (US-trastuzumab).
Christian Schwabe, Chris Wynne, Dayaker Reddy Dyapa, Arpitkumar Prajapati, Disha Dadke   +4 more
doaj   +1 more source

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

Scientific Reports, 2023
The purpose of the study was to assess the prognosis of HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression and investigate the predictors of complete response.
Izzet Dogan, Esra Aydin, Nijat Khanmammadov, Nail Paksoy, Pinar Saip, Adnan Aydiner   +5 more
doaj   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Antibody‐Empowered Nanomedicine for Precise Biomedical Applications

Advanced Science, EarlyView.
This review explores strategies for functionalizing nanoparticles with antibodies to construct antibody‐empowered nanomedicine. It discusses the classification of these nanomedicines based on antibody structure, with a specific focus on their biomedical applications in diagnostics, bioimaging, and therapeutics for various diseases.
Chen Chen, Xinglin Chen, Zhenhao Gao, Meng Sun, Yaozong Yu, Fang Lv, Qiujun Wang, Jinfeng Zhang   +7 more
wiley   +1 more source

Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer. [PDF]

Cancer Innov
Potential biomarkers for the development of targeted radionuclide therapy that can be employed in the treatment of breast cancer have been summarised in the review. They include receptor markers of ER, PR and HER2, as well as other markers of Trop2, PD‐1, EGFR, GRPR and PSMA.
Tan Y, Zeng C, Wang J, Ma F.
europepmc   +2 more sources

Surface‐Coated Inorganic Nanomaterials for Drug Delivery: Chemical Design, Biomedical Applications, and Mechanistic Insights

Advanced NanoBiomed Research, EarlyView.
This review explores how surface‐coated inorganic nanomaterials are chemically engineered for advanced drug delivery. It highlights design principles, coating strategies, and biomedical applications, emphasizing how surface chemistry governs biocompatibility, targeting, and controlled release.
Hossein Daneshgar, Sepideh Ahmadi, Nikzad Abbariki, Navid Rabiee, Sidi A. Bencherif   +4 more
wiley   +1 more source

Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report

BMC Cancer, 2017
Background Trastuzumab-related cardiotoxicity has been reported in patients receiving trastuzumab concurrently with other agents, especially with anthracyclines. Cardiac function damage is generally rare, precox and mild with trastuzumab alone.
Santino Minichillo, Ilaria Gallelli, Elena Barbieri, Marta Cubelli, Daniela Rubino, Sara Quercia, Massimo Dall’Olio, Claudio Rapezzi, Claudio Zamagni   +8 more
doaj   +1 more source

Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA

Drugs - Real World Outcomes, 2023
Background Trastuzumab in combination with chemotherapy is the standard first-line (1L) treatment for HER2+ metastatic gastric cancer (mGC) in the USA.
Afsaneh Barzi, Feng Lin, Jinlin Song, Clara Lam, Xiaoyu Nie, Ahmed Noman, Winghan J. Kwong   +6 more
doaj   +1 more source